Skip to content
2000
image of Integrative Insights into Cancer Progression: Molecular Mechanisms, Epigenetic Regulation, and Emerging Therapeutic Targets

Abstract

Tumor biology has advanced significantly over the last century, mainly due to advances in cellular signaling pathways, genomics, and epigenomics. The study of cancer epigenetics, including DNA methylation, histone modifications, and non-coding RNAs, has shed light on regulatory disturbances that change chromatin structure and gene expression, promoting carcinogenesis. Beyond only genetic alterations, these discoveries uncover new pathways and potential treatment targets. The importance of immune cells, stromal connections, and signaling molecules in influencing tumor growth and resistance has also been highlighted by advancements in tumor microenvironment (TME) profiling. For example, the ERK/MEK/Raf pathway, which is frequently activated in HCC and other malignancies, underscores crucial links between growth factors and cell division, promoting oncogenesis across multiple organs. Advancements in targeted therapies, including small molecules and monoclonal antibodies, have introduced novel approaches to inhibit these pathways and improve patient outcomes, though challenges like therapeutic resistance persist. Emerging resistance mechanisms, such as the activation of alternative pathways, underscore the need for combination therapies and next-generation inhibitors. Furthermore, technologies, such as liquid biopsies using circulating tumor DNA (ctDNA) and computational models for personalized treatment, mark significant strides toward overcoming intratumoral heterogeneity and adaptive resistance. This comprehensive examination of tumor biology highlights the intricate interplay of epigenetic, genetic, and microenvironmental factors in cancer progression, underscoring the continued need for integrative research. Future oncological strategies will likely focus on a multidisciplinary approach, combining genomics, epigenetics, immune modulation, and bioinformatics to develop more effective, individualized therapies against cancer's complex and evolving landscape.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947391658251027060002
2026-02-24
2026-03-10

  • From This Site

    /content/journals/cctr/10.2174/0115733947391658251027060002
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Hickey R. Vouche M. Sze D.Y. Cancer concepts and principles: Primer for the interventional oncologist-part II. J. Vasc. Interv. Radiol. 2013 24 8 1167 1188 10.1016/j.jvir.2013.04.023 23810312
    [Google Scholar]
  2. Preston-Martin S. Pike M.C. Ross R.K. Jones P.A. Henderson B.E. Increased cell division as a cause of human cancer. Cancer Res. 1990 50 23 7415 7421 2174724
    [Google Scholar]
  3. WHO report on cancer: Setting priorities, investing wisely and providing care for all. Geneva, Switzerland: World Health Organization 2020
  4. Sung H. Ferlay J. Siegel R.L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  5. Weinberg R.A. Weinberg R.A. The biology of cancer. United States 2006
    [Google Scholar]
  6. Hanahan D. Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 21376230
    [Google Scholar]
  7. Creighton CJ Making use of cancer genomic databases. Curr Protoc Mol Biol 2018 121 1 14.1 13 10.1002/cpmb.49 29337373
    [Google Scholar]
  8. Yang Y. Dong X. Xie B. Databases and web tools for cancer genomics study. Genom Prote Bioinformat 2015 13 1 46 50 10.1016/j.gpb.2015.01.005 25707591
    [Google Scholar]
  9. Hinkson I.V. Madej B. Stahlberg E.A. Accelerating therapeutics for opportunities in medicine: A paradigm shift in drug discovery. Front. Pharmacol. 2020 11 770 10.3389/fphar.2020.00770 32694991
    [Google Scholar]
  10. Keenan A.B. Wojciechowicz M.L. Wang Z. Connectivity mapping: Methods and applications. Annu. Rev. Biomed. Data Sci. 2019 2 1 69 92 10.1146/annurev‑biodatasci‑072018‑021211
    [Google Scholar]
  11. Piña-Sánchez P. Chávez-González A. Ruiz-Tachiquín M. Cancer biology, epidemiology, and treatment in the 21st century: Current status and future challenges from a biomedical perspective. Cancer Contr. 2021 28 10732748211038735 10.1177/10732748211038735 34565215
    [Google Scholar]
  12. Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018 68 6 394 424 10.3322/caac.21492 30207593
    [Google Scholar]
  13. Ferlay J. Soerjomataram I. Dikshit R. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015 136 5 E359 E386 10.1002/ijc.29210 25220842
    [Google Scholar]
  14. Roberts L.R. Gores G.J. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin. Liver Dis. 2005 25 2 212 225 10.1055/s‑2005‑871200
    [Google Scholar]
  15. Chang F. Steelman L.S. Lee J.T. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia 2003 17 7 1 5
    [Google Scholar]
  16. Yang S. Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol. Lett. 2017 13 3 1041 1047 10.3892/ol.2017.5557 28454211
    [Google Scholar]
  17. Shimamura T. Saito S. Morita K. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J. Gastroenterol. Hepatol. 2000 15 6 640 646 10.1046/j.1440‑1746.2000.02201.x 10921418
    [Google Scholar]
  18. Ng I.O.L. Poon R.T.P. Lee J.M.F. Fan S.T. Ng M. Tso W.K. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol. 2001 116 6 838 845 10.1309/FXNL‑QTN1‑94FH‑AB3A 11764072
    [Google Scholar]
  19. Gollob J.A. Wilhelm S. Carter C. Kelley S.L. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 2006 33 4 392 406
    [Google Scholar]
  20. Galuppo R. Ramaiah D. Ponte O.M. Gedaly R. Molecular therapies in hepatocellular carcinoma: What can we target? Dig. Dis. Sci. 2014 59 8 1688 1697 10.1007/s10620‑014‑3058‑x 24573715
    [Google Scholar]
  21. Moon H. Ro S.W. MAPK/ERK signaling pathway in hepatocellular carcinoma. Cancers 2021 13 12 3026 10.3390/cancers13123026 34204242
    [Google Scholar]
  22. Llovet J.M. Ricci S. Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008 359 4 378 390 10.1056/NEJMoa0708857 18650514
    [Google Scholar]
  23. Cheng A.L. Kang Y.K. Chen Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 10 1 25 34 10.1016/S1470‑2045(08)70285‑7 19095497
    [Google Scholar]
  24. Choi K.J. Baik I.H. Ye S.K. Lee Y.H. Molecular targeted therapy for hepatocellular carcinoma: Present status and future directions. Biol. Pharm. Bull. 2015 38 7 986 991 10.1248/bpb.b15‑00231 26133708
    [Google Scholar]
  25. Philip P.A. Mahoney M.R. Allmer C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 2005 23 27 6657 6663 10.1200/JCO.2005.14.696 16170173
    [Google Scholar]
  26. Geissler E.K. Schnitzbauer A.A. Zülke C. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial. Transplantation 2016 100 1 116 125 10.1097/TP.0000000000000965 26555945
    [Google Scholar]
  27. Johnson P.J. Qin S. Park J.W. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 2013 31 28 3517 3524 10.1200/JCO.2012.48.4410 23980084
    [Google Scholar]
  28. Llovet J.M. Decaens T. Raoul J.L. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 2013 31 28 3509 3516 10.1200/JCO.2012.47.3009 23980090
    [Google Scholar]
  29. Macias H. Hinck L. Mammary gland development. Wiley Interdiscip. Rev. Dev. Biol. 2012 1 4 533 557 10.1002/wdev.35 22844349
    [Google Scholar]
  30. Huebner R.J. Ewald A.J. Cellular foundations of mammary tubulogenesis. Semin. Cell Dev. Biol. 2014 31 124 131 10.1016/j.semcdb.2014.04.019
    [Google Scholar]
  31. Sever R. Brugge J.S. Signal transduction in cancer. Cold Spring Harb. Perspect. Med. 2015 5 4 a006098 10.1101/cshperspect.a006098 25833940
    [Google Scholar]
  32. Hunter T. The age of crosstalk: Phosphorylation, ubiquitination, and beyond. Mol. Cell 2007 28 5 730 738 10.1016/j.molcel.2007.11.019 18082598
    [Google Scholar]
  33. Renoir J.M. Marsaud V. Lazennec G. Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem. Pharmacol. 2013 85 4 449 465 10.1016/j.bcp.2012.10.018 23103568
    [Google Scholar]
  34. Cheskis B.J. Greger J.G. Nagpal S. Freedman L.P. Signaling by estrogens. J. Cell. Physiol. 2007 213 3 610 617 10.1002/jcp.21253 17886255
    [Google Scholar]
  35. Björnström L. Sjöberg M. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 2005 19 4 833 842 10.1210/me.2004‑0486 15695368
    [Google Scholar]
  36. Saha Roy S. Vadlamudi R.K. Role of estrogen receptor signaling in breast cancer metastasis. Int. J. Breast Cancer 2012 2012 1 8 10.1155/2012/654698 22295247
    [Google Scholar]
  37. Oda K Matsuoka Y Funahashi A Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005 1 1 2005.0010 10.1038/msb4100014 16729045
    [Google Scholar]
  38. Sergina N.V. Moasser M.M. The HER family and cancer: Emerging molecular mechanisms and therapeutic targets. Trends Mol. Med. 2007 13 12 527 534 10.1016/j.molmed.2007.10.002 17981505
    [Google Scholar]
  39. Arteaga C.L. Engelman J.A. ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014 25 3 282 303 10.1016/j.ccr.2014.02.025 24651011
    [Google Scholar]
  40. King C.R. Kraus M.H. Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985 229 4717 974 976 10.1126/science.2992089 2992089
    [Google Scholar]
  41. Slamon D.J. Clark G.M. Wong S.G. Levin W.J. Ullrich A. McGuire W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 4785 177 182
    [Google Scholar]
  42. Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes 2024 15 7 903 10.3390/genes15070903 39062682
    [Google Scholar]
  43. Jemal A. Siegel R. Ward E. Murray T. Xu J. Thun M.J. Cancer statistics. CA Cancer J. Clin. 2007 57 1 43 66 10.3322/canjclin.57.1.43 17237035
    [Google Scholar]
  44. Siegel R.L. Miller K.D. Fuchs H.E. Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022 72 1 7 33 10.3322/caac.21708 35020204
    [Google Scholar]
  45. Decker K.F. Zheng D. He Y. Bowman T. Edwards J.R. Jia L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res. 2012 40 21 10765 10779 10.1093/nar/gks888 23019221
    [Google Scholar]
  46. Nelson P.S. Molecular states underlying androgen receptor activation: A framework for therapeutics targeting androgen signaling in prostate cancer. J. Clin. Oncol. 2012 30 6 644 646 10.1200/JCO.2011.39.1300 22184375
    [Google Scholar]
  47. Hsieh A.C. Edlind M.P. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J. Androl. 2014 16 3 378 386 10.4103/1008‑682X.122876 24759575
    [Google Scholar]
  48. Toren P. Zoubeidi A. Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review). Int. J. Oncol. 2014 45 5 1793 1801 10.3892/ijo.2014.2601 25120209
    [Google Scholar]
  49. Faes S. Dormond O. PI3K and AKT: Unfaithful partners in cancer. Int. J. Mol. Sci. 2015 16 9 21138 21152 10.3390/ijms160921138 26404259
    [Google Scholar]
  50. Drake J.M. Graham N.A. Lee J.K. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc. Natl. Acad. Sci. USA 2013 110 49 E4762 E4769 10.1073/pnas.1319948110 24248375
    [Google Scholar]
  51. Kremer C.L. Klein R.R. Mendelson J. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006 66 11 1203 1212 10.1002/pros.20410 16652388
    [Google Scholar]
  52. Shorning B.Y. Dass M.S. Smalley M.J. Pearson H.B. The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. Int. J. Mol. Sci. 2020 21 12 4507 10.3390/ijms21124507 32630372
    [Google Scholar]
  53. Laplante M. Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012 149 2 274 293
    [Google Scholar]
  54. Sancak Y. Thoreen C.C. Peterson T.R. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 2007 25 6 903 915 10.1016/j.molcel.2007.03.003 17386266
    [Google Scholar]
  55. Haar E.V. Lee S. Bandhakavi S. Griffin T.J. Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 2007 9 3 316 323 10.1038/ncb1547 17277771
    [Google Scholar]
  56. Huang J. Wu S. Wu C.L. Manning B.D. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 2009 69 15 6107 6114 10.1158/0008‑5472.CAN‑09‑0975 19602587
    [Google Scholar]
  57. Guertin D.A. Stevens D.M. Saitoh M. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009 15 2 148 159 10.1016/j.ccr.2008.12.017 19185849
    [Google Scholar]
  58. Ardito F. Giuliani M. Perrone D. Troiano G. Muzio L.L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int. J. Mol. Med. 2017 40 2 271 280 10.3892/ijmm.2017.3036 28656226
    [Google Scholar]
  59. Wilson L.J. Linley A. Hammond D.E. New perspectives, opportunities, and challenges in exploring the human protein kinome. Cancer Res. 2018 78 1 15 29 10.1158/0008‑5472.CAN‑17‑2291 29254998
    [Google Scholar]
  60. Roskoski R. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol. Res. 2016 103 26 48 10.1016/j.phrs.2015.10.021 26529477
    [Google Scholar]
  61. Morris S.W. Kirstein M.N. Valentine M.B. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1995 267 5196 316 317 10.1126/science.267.5196.316.c 7824924
    [Google Scholar]
  62. McManus D.T. Catherwood M.A. Carey P.D. Cuthbert R.J.G. Alexander H.D. ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement. Hum. Pathol. 2004 35 10 1285 1288 10.1016/j.humpath.2004.06.001 15492998
    [Google Scholar]
  63. Soda M. Choi Y.L. Enomoto M. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 2007 448 7153 561 566 10.1038/nature05945 17625570
    [Google Scholar]
  64. Cessna M.H. Zhou H. Sanger W.G. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: A study of 135 cases. Mod. Pathol. 2002 15 9 931 938 10.1097/01.MP.0000026615.04130.1F 12218210
    [Google Scholar]
  65. Trinei M. Lanfrancone L. Campo E. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 2000 60 4 793 798 10706082
    [Google Scholar]
  66. Park M. Dean M. Cooper C.S. Mechanism of met oncogene activation. Cell 1986 45 6 895 904 10.1016/0092‑8674(86)90564‑7 2423252
    [Google Scholar]
  67. Baldanzi G. Graziani A. Physiological signaling and structure of the HGF receptor MET. Biomedicines 2014 3 1 1 31 10.3390/biomedicines3010001 28536396
    [Google Scholar]
  68. Organ S.L. Tsao M.S. An overview of the c-MET signaling pathway. Ther. Adv. Med. Oncol. 2011 3 1 Suppl. S7 S19 10.1177/1758834011422556 22128289
    [Google Scholar]
  69. Blumenschein G.R. Mills G.B. Gonzalez-Angulo A.M. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J. Clin. Oncol. 2012 30 26 3287 3296 10.1200/JCO.2011.40.3774 22869872
    [Google Scholar]
  70. Garajová I. Giovannetti E. Biasco G. Peters G.J. c-Met as a target for personalized therapy. Transl. Oncogenomics 2015 7 Suppl. 1 13 31 26628860
    [Google Scholar]
  71. Threadgill D.W. Dlugosz A.A. Hansen L.A. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995 269 5221 230 234 10.1126/science.7618084 7618084
    [Google Scholar]
  72. Blobel C.P. ADAMs: Key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 2005 6 1 32 43 10.1038/nrm1548 15688065
    [Google Scholar]
  73. Salomon D.S. Brandt R. Ciardiello F. Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995 19 3 183 232 10.1016/1040‑8428(94)00144‑I 7612182
    [Google Scholar]
  74. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 2014 79 34 74 10.1016/j.phrs.2013.11.002 24269963
    [Google Scholar]
  75. Gilliland D.G. Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002 100 5 1532 1542 10.1182/blood‑2002‑02‑0492 12176867
    [Google Scholar]
  76. Kiyoi H. Ohno R. Ueda R. Saito H. Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002 21 16 2555 2563 10.1038/sj.onc.1205332 11971190
    [Google Scholar]
  77. Quentmeier H. Reinhardt J. Zaborski M. Drexler H.G. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003 17 1 120 124 10.1038/sj.leu.2402740 12529668
    [Google Scholar]
  78. Daver N. Schlenk R.F. Russell N.H. Levis M.J. Targeting FLT3 mutations in AML: Review of current knowledge and evidence. Leukemia 2019 33 2 299 312 10.1038/s41375‑018‑0357‑9 30651634
    [Google Scholar]
  79. Cocco E. Scaltriti M. Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 2018 15 12 731 747 10.1038/s41571‑018‑0113‑0 30333516
    [Google Scholar]
  80. Nakagawara A. Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett. 2001 169 2 107 114 10.1016/S0304‑3835(01)00530‑4 11431098
    [Google Scholar]
  81. Bertrand T. Kothe M. Liu J. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J. Mol. Biol. 2012 423 3 439 453 10.1016/j.jmb.2012.08.002 22902478
    [Google Scholar]
  82. Brodsky F.M. Monoclonal antibodies as magic bullets. Pharm. Res. 1988 5 1 1 9 10.1023/A:1015860525341 3072552
    [Google Scholar]
  83. Lee Y.T. Tan Y.J. Oon C.E. Molecular targeted therapy: Treating cancer with specificity. Eur. J. Pharmacol. 2018 834 188 196 10.1016/j.ejphar.2018.07.034 30031797
    [Google Scholar]
  84. Oh D.Y. Bang Y.J. HER2-targeted therapies — a role beyond breast cancer. Nat. Rev. Clin. Oncol. 2020 17 1 33 48 10.1038/s41571‑019‑0268‑3 31548601
    [Google Scholar]
  85. Ferguson F.M. Gray N.S. Kinase inhibitors: The road ahead. Nat. Rev. Drug Discov. 2018 17 5 353 377 10.1038/nrd.2018.21 29545548
    [Google Scholar]
  86. Tiwari A. Saraf S. Verma A. Panda P.K. Jain S.K. Novel targeting approaches and signaling pathways of colorectal cancer: An insight. World J. Gastroenterol. 2018 24 39 4428 4435 10.3748/wjg.v24.i39.4428 30357011
    [Google Scholar]
  87. Krishnamurthy N. Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat. Rev. 2018 62 50 60 10.1016/j.ctrv.2017.11.002 29169144
    [Google Scholar]
  88. Westover D Zugazagoitia J Cho BC Lovly CM Paz-Ares L Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 2018 29 i10 9 Suppl. 1 10.1093/annonc/mdx703 29462254
    [Google Scholar]
  89. Smit E.F. Garon E.B. Reck M. Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother. Pharmacol. 2018 82 1 77 86 10.1007/s00280‑018‑3560‑5 29721850
    [Google Scholar]
  90. Pilkington G. Boland A. Brown T. Oyee J. Bagust A. Dickson R. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax 2015 70 4 359 367 10.1136/thoraxjnl‑2014‑205914 25661113
    [Google Scholar]
  91. Lin L. Sabnis A.J. Chan E. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 2015 47 3 250 256 10.1038/ng.3218 25665005
    [Google Scholar]
  92. Rotow J. Bivona T.G. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer 2017 17 11 637 658 10.1038/nrc.2017.84 29068003
    [Google Scholar]
  93. Nussinov R. Tsai C.J. Jang H. Anticancer drug resistance: An update and perspective. Drug Resist. Updat. 2021 59 100796 10.1016/j.drup.2021.100796 34953682
    [Google Scholar]
  94. Rajkomar A. Dean J. Kohane I. Machine learning in medicine. N. Engl. J. Med. 2019 380 14 1347 1358 10.1056/NEJMra1814259 30943338
    [Google Scholar]
  95. LeCun Y. Bengio Y. Hinton G. Deep learning. Nature 2015 521 7553 436 444
    [Google Scholar]
  96. Teare P. Fishman M. Benzaquen O. Toledano E. Elnekave E. Malignancy detection on mammography using dual deep convolutional neural networks and genetically discovered false color input enhancement. J. Digit. Imaging 2017 30 4 499 505 10.1007/s10278‑017‑9993‑2 28656455
    [Google Scholar]
  97. Ehteshami Bejnordi B. Veta M. Johannes van Diest P. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA 2017 318 22 2199 2210 10.1001/jama.2017.14585 29234806
    [Google Scholar]
  98. Esteva A. Kuprel B. Novoa R.A. Dermatologist-level classification of skin cancer with deep neural networks. Nature 2017 542 7639 115 118
    [Google Scholar]
  99. Yu L. Chen H. Dou Q. Qin J. Heng P.A. Automated melanoma recognition in dermoscopy images via very deep residual networks. IEEE Trans. Med. Imaging 2017 36 4 994 1004 10.1109/TMI.2016.2642839 28026754
    [Google Scholar]
  100. Rodriguez-Ruiz A. Lång K. Gubern-Merida A. Stand-alone artificial intelligence for breast cancer detection in mammography: Comparison with 101 radiologists. J. Natl. Cancer Inst. 2019 111 9 916 922 10.1093/jnci/djy222 30834436
    [Google Scholar]
  101. Ueda D. Shimazaki A. Miki Y. Technical and clinical overview of deep learning in radiology. Jpn. J. Radiol. 2019 37 1 15 33 10.1007/s11604‑018‑0795‑3 30506448
    [Google Scholar]
  102. Niazi M.K.K. Parwani A.V. Gurcan M.N. Digital pathology and artificial intelligence. Lancet Oncol. 2019 20 5 e253 e261 10.1016/S1470‑2045(19)30154‑8 31044723
    [Google Scholar]
  103. Zehir A. Benayed R. Shah R.H. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 2017 23 6 703 713 10.1038/nm.4333 28481359
    [Google Scholar]
  104. Hoskinson D.C. Dubuc A.M. Mason-Suares H. The current state of clinical interpretation of sequence variants. Curr. Opin. Genet. Dev. 2017 42 33 39 10.1016/j.gde.2017.01.001 28157586
    [Google Scholar]
  105. Lee J.S. Das A. Jerby-Arnon L. Harnessing synthetic lethality to predict the response to cancer treatment. Nat. Commun. 2018 9 1 2546 10.1038/s41467‑018‑04647‑1 29959327
    [Google Scholar]
  106. Zhou J. Theesfeld C.L. Yao K. Chen K.M. Wong A.K. Troyanskaya O.G. Deep learning sequence-based ab initio prediction of variant effects on expression and disease risk. Nat. Genet. 2018 50 8 1171 1179 10.1038/s41588‑018‑0160‑6 30013180
    [Google Scholar]
/content/journals/cctr/10.2174/0115733947391658251027060002
Loading
Integrative Insights into Cancer Progression: Molecular Mechanisms, Epigenetic Regulation, and Emerging Therapeutic Targets
Bentham Science Publishers ; https://doi.org/10.2174/0115733947391658251027060002
/content/journals/cctr/10.2174/0115733947391658251027060002
/content/journals/cctr/10.2174/0115733947391658251027060002
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: prostate cancer ; molecular targets ; Hepatocellular carcinoma ; non-small cell lung cancer ; signaling pathways ; breast cancer ; pathways

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test